UroGen Pharma Reports P-III Trial (ATLAS) Results of UGN-102 for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Shots:
- The company published the P-III trial results in The Journal of Urology evaluating UGN-102 (mitomycin) for an intravesical solution with/out TURBT vs TURBT alone in a ratio (1:1) in 282 patients at clinical sites in the US, EU & Israel
- The trial met its EPs & showed superiority to TURBT with a 55% reduction of risk for recurrence, progression, or death in patients who received UGN-102, tumor-free CR rate at 3mos. was 65% with UGN-102 vs 64% who underwent TURBT, the estimated probability of remaining event free 15mos. after randomization (72% vs 50%)
- The therapy was well tolerated with a side effect profile similar to prior clinical trials. UGN-102, an investigational drug formulation of mitomycin was developed by using UroGen’s RTGel technology
Ref: Businesswire | Image: Urogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
